Dosimetry doesn't seem to predict the control of organ-confined prostate cancer after I-125 brachytherapy. Evaluation in 150 patients

Archivio Italiano di Urologia e Andrologia

Volumn 81, Issue 4, 2009, Pages 215-217

  Gastaldi, Emilio ^a   Chiono, Luciano ^a   Gallo, Fabrizio ^a   Schenone, Maurizio ^a   Ninotta, Gaetano ^a   Chiarlone, Renato ^a   Ghiso, Giovanni ^a   Giberti, Claudio ^a  

^a IRCCS Istituto Giannina Gaslini   (Italy)

Author keywords

Brachytherapy; Dosimetry; Prostate cancer

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER STAGING; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DOSIMETRY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORGAN WEIGHT; PROSTATE BIOPSY; PROSTATE CANCER; QUESTIONNAIRE;

AGED; BIOPSY; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RADIOMETRY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 76149109178     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy 〈 72Gy, external beam radiotherapy 〉 or = 72Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58:25-33.
2. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 2003; 57:645-653.
3. Potters L, Huang D, Calugaru E, et al. Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology 2003; 62:1073-1077.
4. Stock RG, Stone N. Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur Urol 2002; 41:434-439.
5. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44:789-799.
6. Acher P, Popert MS, Nichol J, Potters L, Morris S, Beaney R. Permanent prostate brachytherapy: dosimetric results and analysis of a learning curve with a dynamic dose-feedback technique. Int J Radiat Oncol Biol Phys 2006; 65:694-698.
7. Lee WR, DeGuzman AF, McMullen KP, McCullough DL. Dosimetry and cancer control after low-dose-rate prostate brachyterapy. Int J Radiat Oncol Biol Phys 2005; 61:52-59.
8. D'Amico AV, Tempany CM, Schultz D, et al. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostate irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology 2003; 62:1063-1067.